General exercise prescription is insufficient for optimal cardiovascular disease prevention, highlighting the need for individualized adjustments by clinicians to maximize clinical benefits.
Does individualized exercise prescription improve CVD prevention compared to general exercise recommendations in patients with or at risk for CVD?
A call to action emphasizing that individualized exercise prescription, rather than a 'one size fits all' approach, is essential for optimal primary and secondary CVD prevention.
In Europe alone, on a yearly basis, millions of people need an appropriate exercise prescription to prevent the occurrence or progression of cardiovascular disease (CVD). A general exercise recommendation can be provided to these individuals (at least 150 min of moderate-intensity endurance exercise, spread over 3-5 days/week, complemented by dynamic moderate-intensity resistance exercise 2 days/week). However, recent evidence shows that this one size does not fit all and that individual adjustments should be made according to the patient's underlying disease(s), risk profile, and individual needs, to maximize the clinical benefits of exercise. In this paper, we (i) argue that this general exercise prescription simply provided to all patients with CVD, or elevated risk for CVD, is insufficient for optimal CVD prevention, and (ii) show that clinicians and healthcare professionals perform heterogeneously when asked to adjust exercise characteristics (e.g. intensity, volume, and type) according to the patient's condition, thereby leading to suboptimal CVD risk factor control. Since exercise training is a class 1A intervention in the primary and secondary prevention of CVD, the awareness of the need to improve exercise prescription has to be raised among clinicians and healthcare professionals if optimized prevention of CVD is ambitioned.
Hansen et al. (Tue,) conducted a review in Cardiovascular disease. Individualized exercise prescription vs. General exercise recommendation was evaluated. General exercise prescription is insufficient for optimal cardiovascular disease prevention, highlighting the need for individualized adjustments by clinicians to maximize clinical benefits.